Publications
Isser A, Silver AB, Pruitt HC, et al. Nanoparticle-based modulation of CD4+ T cell effector and helper functions enhances adoptive immunotherapy. Nat Commun. 2022;13(1):6086. Published 2022 Oct 14. doi:10.1038/s41467-022-33597-y
Chaisawangwong W, Wang H, Kouo T, et al. Cross-reactivity of SARS-CoV-2- and influenza A-specific T cells in individuals exposed to SARS-CoV-2. JCI Insight. 2022;7(18):e158308. Published 2022 Sep 22. doi:10.1172/jci.insight.158308
VanDyke D, Taylor JD, Kaeo KJ, Hunt J, Spangler JB. Biologics-based degraders – an expanding toolkit for targeted-protein degradation [published online ahead of print, 2022 Sep 27]. Curr Opin Biotechnol. 2022;78:102807. doi:10.1016/j.copbio.2022.102807
Luly KM, Yang H, Lee SJ, et al. Poly(Beta-Amino Ester)s as High-Yield Transfection Reagents for Recombinant Protein Production. Int J Nanomedicine. 2022;17:4469-4479. Published 2022 Sep 23. doi:10.2147/IJN.S377371
Li S, Hu Y, Li A, et al. Payload distribution and capacity of mRNA lipid nanoparticles. Nat Commun. 2022;13(1):5561. Published 2022 Sep 23. doi:10.1038/s41467-022-33157-4
Zhu Y, Shen R, Vuong I, et al. Multi-step screening of DNA/lipid nanoparticles and co-delivery with siRNA to enhance and prolong gene expression. Nat Commun. 2022;13(1):4282. Published 2022 Jul 25. doi:10.1038/s41467-022-31993-y
Casciola-Rosen L, Thiemann DR, Andrade F, et al. IgM anti-ACE2 autoantibodies in severe COVID-19 activate complement and perturb vascular endothelial function. JCI Insight. 2022;7(9):e158362. Published 2022 May 9. doi:10.1172/jci.insight.158362
Li L, Zhang Y, Zhou Y, et al. Quaternary nanoparticles enable sustained release of bortezomib for hepatocellular carcinoma [published online ahead of print, 2022 May 21]. Hepatology. 2022;10.1002/hep.32584. doi:10.1002/hep.32584
de Rutte J, Dimatteo R, Archang MM, et al. Suspendable Hydrogel Nanovials for Massively Parallel Single-Cell Functional Analysis and Sorting [published online ahead of print, 2022 Mar 24]. ACS Nano. 2022;10.1021/acsnano.1c11420. doi:10.1021/acsnano.1c11420
Singh AK, Praharaj M, Lombardo KA, et al. Re-engineered BCG overexpressing cyclic di-AMP augments trained immunity and exhibits improved efficacy against bladder cancer. Nat Commun. 2022;13(1):878. Published 2022 Feb 15. doi:10.1038/s41467-022-28509-z
Ludwig SD, Bernstein ZJ, Agatemor C, et al. A versatile design platform for glycoengineering therapeutic antibodies. MAbs. 2022;14(1):2095704. doi:10.1080/19420862.2022.2095704
Dammen-Brower K, Epler P, Zhu S, et al. Strategies for Glycoengineering Therapeutic Proteins. Front Chem. 2022;10:863118. Published 2022 Apr 13. doi:10.3389/fchem.2022.863118
Almodovar Cruz GE, Kaunitz G, Stein JE, et al. Immune cell subsets in interface cutaneous immune-related adverse events associated with anti-PD-1 therapy resemble acute graft versus host disease more than lichen planus. J Cutan Pathol. 2022;49(8):701-708. doi:10.1111/cup.14242
VanDyke D, Iglesias M, Tomala J, et al. Engineered human cytokine/antibody fusion proteins expand regulatory T cells and confer autoimmune disease protection. Cell Rep. 2022;41(3):111478. doi:10.1016/j.celrep.2022.111478
Sargunas PR, Spangler JB. Joined at the hip: The role of light chain complementarity determining region 2 in antibody self-association. Proc Natl Acad Sci U S A. 2022;119(28):e2208330119. doi:10.1073/pnas.2208330119
Krohl PJ, Spangler JB. A Hybrid Adherent/Suspension Cell-Based Selection Strategy for Discovery of Antibodies Targeting Membrane Proteins. Methods Mol Biol. 2022;2491:195-216. doi:10.1007/978-1-0716-2285-8_11
Paul S, Pearlman AH, Douglass J, et al. TCR β chain-directed bispecific antibodies for the treatment of T cell cancers. Sci Transl Med. 2021;13(584):eabd3595. doi:10.1126/scitranslmed.abd3595
Hwang MS, Miller MS, Thirawatananond P, et al. Structural engineering of chimeric antigen receptors targeting HLA-restricted neoantigens. Nat Commun. 2021;12(1):5271. Published 2021 Sep 6. doi:10.1038/s41467-021-25605-4
Douglass J, Hsiue EH, Mog BJ, et al. Bispecific antibodies targeting mutant RAS neoantigens. Sci Immunol. 2021;6(57):eabd5515. doi:10.1126/sciimmunol.abd5515
Berry S, Giraldo NA, Green BF, et al. Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockade. Science. 2021;372(6547):eaba2609. doi:10.1126/science.aba2609
Hsiue EH, Wright KM, Douglass J, et al. Targeting a neoantigen derived from a common TP53 mutation. Science. 2021;371(6533):eabc8697. doi:10.1126/science.abc8697
Caushi JX, Zhang J, Ji Z, et al. Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers [published correction appears in Nature. 2021 Oct;598(7881):E1]. Nature. 2021;596(7870):126-132. doi:10.1038/s41586-021-03752-4
Hu Y, Zhu Y, Sutherland ND, et al. Size-Controlled and Shelf-Stable DNA Particles for Production of Lentiviral Vectors. Nano Lett. 2021;21(13):5697-5705. doi:10.1021/acs.nanolett.1c01421
Liu HW, Hu Y, Ren Y, et al. Scalable Purification of Plasmid DNA Nanoparticles by Tangential Flow Filtration for Systemic Delivery. ACS Appl Mater Interfaces. 2021;13(26):30326-30336. doi:10.1021/acsami.1c05750
Ahn HH, Carrington C, Hu Y, et al. Nanoparticle-mediated tumor cell expression of mIL-12 via systemic gene delivery treats syngeneic models of murine lung cancers. Sci Rep. 2021;11(1):9733. Published 2021 May 6. doi:10.1038/s41598-021-89124-4
Ahn HH, Carrington C, Hu Y, et al. Nanoparticle-mediated tumor cell expression of mIL-12 via systemic gene delivery treats syngeneic models of murine lung cancers. Sci Rep. 2021;11(1):9733. Published 2021 May 6. doi:10.1038/s41598-021-89124-4 (work enabled by the center).
Berry S, Giraldo NA, Green BF, et al. Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockade. Science. 2021;372(6547):eaba2609. doi:10.1126/science.aba2609
Dykema AG, Zhang B, Woldemeskel BA, et al. Functional characterization of CD4+ T cell receptors crossreactive for SARS-CoV-2 and endemic coronaviruses. J Clin Invest. 2021;131(10):e146922. doi:10.1172/JCI146922
Est-Witte SE, Farris AL, Tzeng SY, et al. Non-viral gene delivery of HIF-1α promotes angiogenesis in human adipose-derived stem cells. Acta Biomater. 2020;113:279-288. doi:10.1016/j.actbio.2020.06.042
Green JJ. Immunoengineering has arrived. J Biomed Mater Res A. 2021;109(4):397-403. doi:10.1002/jbm.a.37041
Hou J, Yang R, Vuong I, Li F, Kong J, Mao HQ. Biomaterials strategies to balance inflammation and tenogenesis for tendon repair. Acta Biomater. 2021;130:1-16. doi:10.1016/j.actbio.2021.05.043 (work enabled by the center).
Howard GP, Bender NG, Khare P, et al. Immunopotentiation by lymph-node targeting of a malaria transmission-blocking nanovaccine. Front Immunol. 2021;12:729086. Published 2021 Aug 27. doi:10.3389/fimmu.2021.729086 (work enabled by the center).
Isser A, Livingston NK, Schneck JP. Biomaterials to enhance antigen-specific T cell expansion for cancer immunotherapy. Biomaterials. 2021;268:120584. doi:10.1016/j.biomaterials.2020.120584
Karlsson J, Rhodes KR, Green JJ, Tzeng SY. Poly(beta-amino ester)s as gene delivery vehicles: challenges and opportunities. Expert Opin Drug Deliv. 2020;17(10):1395-1410. doi:10.1080/17425247.2020.1796628
Karlsson J, Tzeng SY, Hemmati S, et al. Photocrosslinked bioreducible polymeric nanoparticles for enhanced systemic siRNA delivery as cancer therapy. Adv Funct Mater. 2021;31(17):2009768. doi:10.1002/adfm.202009768
Kim J, Vaughan HJ, Zamboni CG, Sunshine JC, Green JJ. High-throughput evaluation of polymeric nanoparticles for tissue-targeted gene expression using barcoded plasmid DNA. J Control Release. 2021;337:105-116. doi:10.1016/j.jconrel.2021.05.047
Leone RD, Powell JD. Fueling the Revolution: Targeting metabolism to enhance immunotherapy. Cancer Immunol Res. 2021;9(3):255-260. doi:10.1158/2326-6066.CIR-20-0791
Luly KM, Choi J, Rui Y, Green JJ, Jackson EM. Safety considerations for nanoparticle gene delivery in pediatric brain tumors. Nanomedicine (Lond). 2020;15(18):1805-1815. doi:10.2217/nnm-2020-0110
McCurdy SR, Radojcic V, Tsai HL, et al. Signatures of GVHD and relapse after post-transplant cyclophosphamide revealed by immune profiling and machine learning [published online ahead of print, 2021 Oct 17]. Blood. 2021;blood.2021013054.
Mo F, Yu Z, Li P, et al. An engineered IL-2 partial agonist promotes CD8+ T cell stemness. Nature. 2021;597(7877):544-548. doi:10.1038/s41586-021-03861-0
Neshat SY, Tzeng SY, Green JJ. Gene delivery for immunoengineering. Curr Opin Biotechnol. 2020;66:1-10. doi:10.1016/j.copbio.2020.05.008
Rhodes KR, Isser A, Hickey JW, et al. Biodegradable cationic polymer blends for fabrication of enhanced artificial antigen presenting cells to treat melanoma. ACS Appl Mater Interfaces. 2021;13(7):7913-7923. doi:10.1021/acsami.0c19955
Rhodes KR, Meyer RA, Wang J, Tzeng SY, Green JJ. Biomimetic tolerogenic artificial antigen presenting cells for regulatory T cell induction. Acta Biomater. 2020;112:136-148. doi:10.1016/j.actbio.2020.06.004
Routkevitch D, Sudhakar D, Conge M, et al. Efficiency of cytosolic delivery with Poly(β-amino ester) nanoparticles is dependent on the effective pKa of the polymer. ACS Biomater Sci Eng. 2020;6(6):3411-3421. doi:10.1021/acsbiomaterials.0c00271
Shenderov K, Collins SL, Powell JD, Horton MR. Immune dysregulation as a driver of idiopathic pulmonary fibrosis. J Clin Invest. 2021;131(2):e143226. doi:10.1172/JCI143226
Thompson EA, Cascino K, Ordonez AA, et al. Metabolic programs define dysfunctional immune responses in severe COVID-19 patients. Cell Rep. 2021;34(11):108863. doi:10.1016/j.celrep.2021.108863
Thompson EA, Powell JD. Inhibition of the adenosine pathway to potentiate cancer immunotherapy: Potential for combinatorial approaches. Annu Rev Med. 2021;72:331-348. doi:10.1146/annurev-med-060619-02315
Tzeng SY, Patel KK, Wilson DR, Meyer RA, Rhodes KR, Green JJ. In situ genetic engineering of tumors for long-lasting and systemic immunotherapy. Proc Natl Acad Sci U S A. 2020;117(8):4043-4052. doi:10.1073/pnas.1916039117
Vaughan HJ, Zamboni CG, Radant NP, et al. Poly(beta-amino ester) nanoparticles enable tumor-specific TRAIL secretion and a bystander effect to treat liver cancer. Mol Ther Oncolytics. 2021;21:377-388. Published 2021 Apr 16. doi:10.1016/j.omto.2021.04.004
Commensal bacteria stimulate antitumor responses via T cell cross-reactivity. JCI Insight. 2020 Apr 23;5(8). doi: 10.1172/jci.insight.135597.
Targeting Metabolism as a Platform for Inducing Allograft Tolerance in the Absence of Long-Term Immunosuppression. Front Immunol. 2020;11:572. doi: 10.3389/fimmu.2020.00572.
Oh MH, Sun IH, Zhao L, Leone RD, Sun IM, Xu W, Collins SL, Tam AJ, Blosser RL, Patel CH, Englert JM, Arwood ML, Wen J, Chan-Li Y, Tenora L, Majer P, Rais R, Slusher BS, Horton MR, Powell JD. Targeting glutamine metabolism enhances tumor specific immunity by modulating suppressive myeloid cells [published online ahead of print, 2020 Apr 23]. J Clin Invest. 2020;131859. doi:10.1172/JCI131859
Ichikawa J, Yoshida T, Isser A, Laino AS, Vassallo M, Woods D, Kim S, Oelke M, Jones K, Schneck JP, Weber JS. Rapid Expansion of Highly Functional Antigen-Specific T cells from Melanoma Patients by Nanoscale Artificial Antigen Presenting Cells. Clin Cancer Res. 2020 Apr 2;. doi: 10.1158/1078-0432.CCR-19-3487.
Tzeng SY, Patel KK, Wilson DR, Meyer RA, Rhodes KR, Green JJ. In situ genetic engineering of tumors for long-lasting and systemic immunotherapy. Proc Natl Acad Sci U S A. 2020 Feb 7;. doi: 10.1073/pnas.1916039117.
Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion. Science. 2019 Nov 22;366(6468):1013-1021. doi: 10.1126/science.aav2588. Epub 2019 Nov 7.
Targeting metabolism to regulate immune responses in autoimmunity and cancer. Nat Rev Drug Discov. 2019 Sep;18(9):669-688. doi: 10.1038/s41573-019-0032-5. Epub 2019 Jul 30. Review.